GO:1904977 lymphatic endothelial cell migration: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904977 describes the orderly movement of a lymphatic endothelial cell from one site to another within the wall of a lymphatic vessel.
• Lymphatic endothelial cell migration is a specialized form of cell motility that drives lymphangiogenesis during development and disease.
• Key molecular drivers include ANGPT2, ITGB1, RhoA, formins, EGFL7, integrin αvβ3, and the transcription factors MAFB and MAFBB.
• Localized extracellular matrix deposition, such as Collagen2a1, provides directional cues for migrating lymphatic endothelial cells.
• Dysregulated lymphatic endothelial cell migration contributes to tumor lymphangiogenesis, lymphatic metastasis, and acquired drug resistance.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of genes controlling lymphatic endothelial cell migration.
Description
Lymphatic endothelial cell migration (GO:1904977) is the biological process in which a lymphatic endothelial cell moves in an orderly manner from one site to another within the wall of a lymphatic vessel. This process is fundamental to the formation and remodeling of the lymphatic vasculature, a network that returns interstitial fluid to the bloodstream and serves as a conduit for immune cell trafficking. Unlike general cell migration, this term specifically refers to the directed movement of lymphatic endothelial cells within the lymphatic vessel wall, a context that imposes unique mechanical and biochemical constraints. Researchers study GO:1904977 because it is a critical step in lymphangiogenesis, the growth of new lymphatic vessels from pre-existing ones, and because its dysregulation is linked to cancer progression, lymphedema, and inflammatory diseases. Understanding the molecular control of lymphatic endothelial cell migration requires integrating signals from growth factors, extracellular matrix components, and cell adhesion molecules. Recent studies have identified specific genes and pathways that govern this process, including angiopoietin-2 (ANGPT2), β1 integrin (ITGB1), RhoA, formins, epidermal growth factor-like domain 7 (EGFL7), and the transcription factors MAFB and MAFBB. These discoveries have been made possible by advances in genetic model organisms, live imaging, and CRISPR-based genome editing. This article provides a research-grade overview of GO:1904977, covering its definition, molecular mechanisms, key genes, disease relevance, and the experimental methods used to study it.
lymphatic endothelial cell migration At A Glance
| GO ID | GO:1904977 |
|---|---|
| GO term | lymphatic endothelial cell migration |
| Ontology | biological_process |
| Synonym | None |
| Major function | Orderly movement of lymphatic endothelial cells within the lymphatic vessel wall, essential for lymphangiogenesis and lymphatic vessel remodeling |
| Cellular context | Lymphatic endothelial cells lining lymphatic vessels |
| Key molecular drivers | ANGPT2, ITGB1, RhoA, formins, EGFL7, integrin αvβ3, MAFB, MAFBB, Collagen2a1 |
| Associated processes | Lymphangiogenesis, cell adhesion, extracellular matrix remodeling, cytoskeletal dynamics |
| Disease relevance | Cancer metastasis, lymphedema, inflammatory lymphangiogenesis, acquired drug resistance |
What Is GO:1904977?
According to the Gene Ontology, GO:1904977 (lymphatic endothelial cell migration) is defined as the orderly movement of a lymphatic endothelial cell from one site to another in the wall of a lymphatic vessel. This definition emphasizes three key elements: the cell type (lymphatic endothelial cell), the directionality and orderliness of movement, and the spatial context (the wall of a lymphatic vessel). It is a biological process term, meaning it describes a series of molecular events rather than a static structure or a single molecular function. The term does not have synonyms in the QuickGO database. In practice, this process is observed during embryonic lymphangiogenesis, where lymphatic endothelial cells migrate to form the primitive lymphatic plexus, and in adult tissues during inflammation or tumor-associated lymphangiogenesis.
Why Is lymphatic endothelial cell migration Important in Cell Biology?
Lymphatic endothelial cell migration is essential for the development and maintenance of the lymphatic vascular system, which regulates tissue fluid homeostasis, immune surveillance, and lipid absorption. Defects in this process cause lymphatic dysplasia and lymphedema, while excessive or misdirected migration contributes to tumor lymphangiogenesis and metastatic spread. Because lymphatic vessels are the primary route for cancer cell dissemination, understanding the molecular control of lymphatic endothelial cell migration has direct implications for cancer prognosis and therapy. Moreover, this process is a paradigm for studying how cells integrate chemical and mechanical cues to achieve directed movement within a tissue.
• Drives embryonic lymphangiogenesis and formation of the lymphatic vasculature.
• Maintains lymphatic vessel integrity and function in adult tissues.
• Promotes tumor-associated lymphangiogenesis, facilitating lymphatic metastasis.
• Contributes to acquired drug resistance in breast cancer through RGS5+ lymphatic endothelial cells.
• Is regulated by extracellular matrix components such as Collagen2a1, which provide directional cues.
• Involves growth factor signaling through ANGPT2 and its receptor TIE2.
• Requires integrin-mediated adhesion, including β1 integrin and integrin αvβ3.
• Depends on RhoA and formin-mediated actin cytoskeletal remodeling.
• Is controlled by transcription factors such as MAFB and MAFBB in a topographically distinct manner.
• Serves as a target for anti-lymphangiogenic therapies in cancer and inflammatory diseases.
What Happens During lymphatic endothelial cell migration?
Initiation and directional sensing
In simple terms: The cell receives a signal telling it where to go.
Lymphatic endothelial cell migration begins when a cell perceives a directional cue, often a growth factor or chemokine gradient. Angiopoietin-2 (ANGPT2) acts as a chemoattractant that stimulates lymphatic endothelial cell migration through its receptor TIE2. In the zebrafish embryo, localized secretion of Collagen2a1 provides a directional cue that supports lymphatic endothelial cell migration. Epidermal growth factor-like domain 7 (EGFL7) drives brain lymphatic endothelial cell development through integrin αvβ3, indicating that multiple ligand-receptor systems can initiate migration in a tissue-specific manner. These signals converge on intracellular pathways that establish cell polarity and orient the cytoskeleton toward the direction of movement.
Adhesion and extracellular matrix interaction
In simple terms: The cell grips the surrounding matrix to pull itself forward.
Migrating lymphatic endothelial cells must adhere to and remodel the extracellular matrix. β1 integrin (ITGB1) is a key adhesion receptor that mediates lymphatic endothelial cell migration downstream of ANGPT2 signaling. Integrin αvβ3 similarly supports brain lymphatic endothelial cell development in response to EGFL7. Collagen2a1 is secreted locally and deposited in the matrix to support migration in the zebrafish embryo. These adhesion events are dynamic, with the cell forming new attachments at the leading edge and releasing them at the rear to allow forward movement.
Cytoskeletal remodeling and force generation
In simple terms: The cell's internal skeleton rearranges to push and pull it forward.
Actin cytoskeletal dynamics provide the mechanical force for migration. ANGPT2-induced lymphatic endothelial cell migration requires the β1 integrin-RhoA-formin axis, in which RhoA activates formin proteins to nucleate actin filaments. This pathway leads to the formation of filopodia and lamellipodia that drive membrane protrusion at the leading edge. The transcription factors MAFB and MAFBB differentially regulate lymphatic endothelial cell migration in topographically distinct manners, likely by controlling the expression of cytoskeletal and adhesion genes. The coordinated assembly and disassembly of actin networks, together with myosin-based contraction, generate the traction forces needed for translocation.
Regulation by transcription factors
In simple terms: Master switches in the cell's nucleus control which migration genes are turned on.
The transcription factors MAFB and MAFBB (also known as Mafb and Mafbb in zebrafish) differentially regulate lymphatic endothelial cell migration in topographically distinct manners. This suggests that distinct transcriptional programs operate in different lymphatic vessel beds or at different developmental stages. These factors likely control the expression of genes involved in cell adhesion, cytoskeletal dynamics, and signaling, thereby shaping the migratory behavior of lymphatic endothelial cells. Their differential regulation highlights the heterogeneity of lymphatic endothelial cell migration across tissues.
Integration with lymphangiogenesis
In simple terms: Individual cell movements add up to form new lymphatic vessels.
Lymphatic endothelial cell migration is a core component of lymphangiogenesis, the process by which new lymphatic vessels sprout from existing ones. During embryonic development, lymphatic endothelial cells migrate collectively to form the primitive lymphatic plexus, which later remodels into a hierarchical network. In adults, this process is largely quiescent but can be reactivated during inflammation, wound healing, and tumor growth. The migration of individual cells must be coordinated with proliferation, survival, and tube formation to produce functional vessels. Dysregulation of any of these steps can lead to lymphatic malformations or pathological lymphangiogenesis.
Key Genes Involved in GO:1904977 lymphatic endothelial cell migration
The following genes and proteins have been experimentally implicated in the regulation of lymphatic endothelial cell migration (GO:1904977).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANGPT2 | Secreted growth factor that stimulates lymphatic endothelial cell migration via TIE2 | Target for anti-lymphangiogenic therapy; studied in angiogenesis and lymphangiogenesis |
| ITGB1 | β1 integrin subunit mediating cell-matrix adhesion during migration | Required for ANGPT2-induced migration; potential target in cancer and lymphedema |
| RHOA | Small GTPase that activates formins to drive actin polymerization | Central node in migratory signaling; studied in cytoskeletal dynamics |
| FMN1 | Formin family protein that nucleates actin filaments | Effector of RhoA in migration; potential drug target |
| EGFL7 | Secreted factor that promotes brain lymphatic endothelial cell development via integrin αvβ3 | Regulates developmental lymphangiogenesis; studied in neurovascular biology |
| ITGAV | Integrin αv subunit partnering with β3 to bind EGFL7 | Mediates EGFL7-dependent migration; target in brain lymphatic disorders |
| ITGB3 | Integrin β3 subunit partnering with αv to bind EGFL7 | Mediates EGFL7-dependent migration; target in brain lymphatic disorders |
| MAFB | Transcription factor that differentially regulates lymphatic endothelial cell migration | Controls topographically distinct migratory programs; studied in zebrafish |
| MAFBB | Transcription factor paralog of MAFB with distinct migratory functions | Regulates migration in a topographically distinct manner; studied in zebrafish |
| COL2A1 | Extracellular matrix collagen that provides directional cues for migration | Localized secretion supports migration; studied in zebrafish development |
| RGS5 | Regulator of G protein signaling in lymphatic endothelial cells | Promotes metastasis and drug resistance in breast cancer |
| PAI-1 | Serpin that induces endothelial-to-mesenchymal transition in lymphatic endothelial cells | Promotes lymphatic metastasis; derived from cancer-associated fibroblasts |
| COL1A1 | Collagen type I alpha 1 chain in endothelial cells | Associated with endothelial-to-mesenchymal transition and gastric cancer progression |
| ANGPTL4 | Angiopoietin-like 4 protein involved in endothelial-to-mesenchymal transition | Drives gastric cancer progression via SDC4 axis |
| SDC4 | Syndecan-4 proteoglycan receptor for ANGPTL4 | Mediates signaling in endothelial-to-mesenchymal transition |
| FOXC2 | Transcription factor involved in lymphatic valve development and migration | Studied in lymphatic dysplasia and lymphedema (contextual) |
| PROX1 | Master transcription factor for lymphatic endothelial cell identity | Essential for lymphatic endothelial cell specification and migration (contextual) |
| VEGFR3 | Receptor tyrosine kinase for VEGF-C/D that drives lymphangiogenesis | Central regulator of lymphatic endothelial cell migration and survival (contextual) |
How Is lymphatic endothelial cell migration Regulated?
Lymphatic endothelial cell migration is regulated by a combination of growth factor signaling, cell adhesion, and transcriptional control. ANGPT2 activates TIE2, which signals through β1 integrin to activate RhoA and formins, driving actin polymerization and migration. EGFL7 signals through integrin αvβ3 to promote brain lymphatic endothelial cell development. Localized Collagen2a1 secretion provides spatial regulation of migration in the zebrafish embryo. The transcription factors MAFB and MAFBB differentially regulate migration in topographically distinct manners, indicating that transcriptional programs are tailored to specific vascular beds. In pathological settings, cancer-associated fibroblast-derived PAI-1 induces endothelial-to-mesenchymal transition in lymphatic endothelial cells, enhancing lymphatic metastasis. RGS5+ lymphatic endothelial cells promote breast cancer metastasis and acquired drug resistance through oxidative stress-sensing mechanisms. These regulatory layers ensure that lymphatic endothelial cell migration is tightly controlled in space and time.
lymphatic endothelial cell migration and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RGS5 | Breast cancer metastasis and acquired drug resistance | Knockout or overexpression in lymphatic endothelial cells; xenograft models |
| PAI-1 | Lymphatic metastasis via endothelial-to-mesenchymal transition | Knockout in cancer-associated fibroblasts; co-culture with lymphatic endothelial cells |
| COL1A1 | Gastric cancer progression via ANGPTL4-SDC4 axis | Knockout or knockdown in endothelial cells; gastric cancer models |
| ANGPT2 | Lymphangiogenesis and tumor metastasis | Knockout or point mutation in mice; lymphatic endothelial cell migration assays |
| EGFL7 | Brain lymphatic endothelial cell development | Knockout in zebrafish or mice; brain lymphatic imaging |
Cancer metastasis and lymphangiogenesis
Lymphatic endothelial cell migration is a critical step in tumor-associated lymphangiogenesis, which facilitates the spread of cancer cells to regional lymph nodes and distant organs. RGS5+ lymphatic endothelial cells promote metastasis and acquired drug resistance in breast cancer through oxidative stress-sensing mechanisms. Cancer-associated fibroblast-derived PAI-1 induces endothelial-to-mesenchymal transition in lymphatic endothelial cells, enhancing lymphatic metastasis. In gastric cancer, COL1A1-positive endothelial cells promote progression via the ANGPTL4-SDC4 axis driven by endothelial-to-mesenchymal transition. These findings highlight lymphatic endothelial cell migration as a therapeutic target in oncology.
Lymphedema and lymphatic dysplasia
Impaired lymphatic endothelial cell migration during development or after injury can lead to lymphedema, a chronic condition characterized by fluid accumulation and tissue swelling. While specific mutations in migration-related genes have not been fully characterized in human lymphedema, the fundamental role of lymphatic endothelial cell migration in lymphatic vessel formation suggests that defects in this process contribute to lymphatic dysplasia. Model organisms such as zebrafish have been instrumental in identifying genes required for lymphatic endothelial cell migration, including Collagen2a1, MAFB, and MAFBB.
Inflammatory lymphangiogenesis
Inflammation triggers lymphangiogenesis, and lymphatic endothelial cell migration is essential for the expansion of lymphatic networks in inflamed tissues. Regulatory T cells crosstalk with endothelial cells to modulate vascular behavior, including lymphatic vessel remodeling. Dysregulated inflammatory lymphangiogenesis contributes to conditions such as rheumatoid arthritis, inflammatory bowel disease, and transplant rejection. Understanding how lymphatic endothelial cell migration is controlled in inflammatory contexts may reveal new therapeutic opportunities.
From lymphatic endothelial cell migration-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is ANGPT2 required for lymphatic endothelial cell migration? | ANGPT2 knockout mice or zebrafish; lymphatic endothelial cell migration assays |
| Does the ITGB1-RhoA-formin axis mediate migration? | ITGB1 conditional knockout; RhoA or formin point mutations; live imaging |
| What is the role of EGFL7-integrin αvβ3 signaling in brain lymphatic development? | EGFL7 knockout zebrafish; integrin αvβ3 knock-in reporters |
| How do MAFB and MAFBB differentially regulate migration? | mafba/mafbb double knockout zebrafish; single-cell RNA-seq |
| Does Collagen2a1 provide directional cues for migration? | Col2a1 knockout zebrafish; local secretion reporters |
| Can overexpression of RGS5 enhance lymphatic metastasis? | RGS5 overexpression in lymphatic endothelial cells; breast cancer xenografts |
How to Study the lymphatic endothelial cell migration Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live imaging (zebrafish, mouse) | Real-time movement of lymphatic endothelial cells in vivo | Studying developmental and pathological migration |
| Transwell migration assay | Number of cells migrating through a membrane toward a chemoattractant | Testing growth factor-induced migration (e.g., ANGPT2) |
| Scratch wound assay | Rate of cell migration into a denuded area | Assessing collective migration and wound healing |
| CRISPR knockout screen | Genes required for migration | Unbiased discovery of migration regulators |
| RNA-seq / scRNA-seq | Transcriptional profiles of migrating cells | Identifying migration-associated gene signatures |
| Proteomics | Protein expression and modifications | Mapping signaling pathways in migration |
| Immunofluorescence | Localization of proteins (e.g., integrins, actin) | Visualizing cytoskeletal and adhesion dynamics |
| Genetic lineage tracing | Origin and fate of migrating lymphatic endothelial cells | Tracking cell movements during development |
Live imaging of lymphatic endothelial cell migration
Live imaging in model organisms such as zebrafish and mice allows direct visualization of lymphatic endothelial cell migration in vivo. Fluorescent reporters for lymphatic endothelial cells (e.g., Prox1, Lyve1) enable tracking of individual cell movements over time. These studies have revealed that lymphatic endothelial cells migrate in a directed, orderly manner within the vessel wall, guided by local cues such as Collagen2a1. Live imaging can be combined with genetic perturbations to test the role of specific genes in migration.
In vitro migration assays
Transwell migration and scratch wound assays are commonly used to measure lymphatic endothelial cell migration in vitro. These assays can be performed with primary lymphatic endothelial cells or cell lines, and are useful for testing the effects of growth factors such as ANGPT2 or inhibitors of specific signaling pathways. Boyden chamber assays can assess chemotaxis toward gradients of ANGPT2 or other chemoattractants. These methods provide quantitative readouts of migration speed, directionality, and persistence.
Genetic and CRISPR screens
CRISPR-based knockout screens enable unbiased identification of genes required for lymphatic endothelial cell migration. Pooled or arrayed screens can be performed in lymphatic endothelial cell lines or primary cells, followed by migration assays and next-generation sequencing to identify enriched or depleted sgRNAs. Candidate genes can then be validated individually using knockout, knock-in, or overexpression models. Zebrafish models are particularly amenable to CRISPR-based gene editing for studying lymphatic development.
Transcriptomics and proteomics
RNA sequencing (RNA-seq) of migrating versus non-migrating lymphatic endothelial cells can reveal transcriptional programs underlying migration. Single-cell RNA-seq has been used to identify distinct lymphatic endothelial cell subpopulations with different migratory capacities. Proteomic approaches can identify post-translational modifications and protein-protein interactions that regulate migration. These omics methods complement genetic and imaging studies to provide a systems-level view of lymphatic endothelial cell migration.
How CRISPR Can Be Used to Study GO:1904977 lymphatic endothelial cell migration
Knockout
CRISPR knockout of genes such as ANGPT2, ITGB1, RHOA, or EGFL7 in lymphatic endothelial cells or model organisms can abolish or impair lymphatic endothelial cell migration, providing causal evidence for their requirement. Knockout zebrafish for mafba and mafbb display distinct migration defects, revealing differential regulation. Knockout of Col2a1 in zebrafish disrupts directional migration. These models are essential for validating candidate genes identified in screens.
Point Mutation
CRISPR-mediated point mutations can be used to dissect specific phosphorylation sites, GTPase-activating mutations, or ligand-binding residues in proteins that regulate lymphatic endothelial cell migration. For example, point mutations in RHOA that lock it in an active or inactive state can test its role in migration. Point mutations in integrin β1 that disrupt talin binding can separate adhesion from signaling functions. These precise edits provide mechanistic insights beyond simple knockout.
Knock-in
Knock-in of fluorescent reporters (e.g., GFP, mCherry) into endogenous loci such as PROX1 or LYVE1 enables real-time visualization of lymphatic endothelial cell migration in vivo. Knock-in of epitope tags (e.g., HA, FLAG) allows biochemical purification and interaction studies. Knock-in of Cre recombinase or other effectors can be used for lineage tracing or conditional manipulation. These models are invaluable for studying migration dynamics in intact tissues.
Overexpression
Overexpression of genes such as RGS5 or PAI-1 in lymphatic endothelial cells can enhance migration and promote metastasis in cancer models. Overexpression of constitutively active RhoA or formins can drive excessive actin polymerization and migration. Overexpression of EGFL7 or integrin αvβ3 can promote brain lymphatic endothelial cell development. These gain-of-function models complement loss-of-function studies to establish sufficiency.
How EDITGENE Supports lymphatic endothelial cell migration Research
Researchers studying lymphatic endothelial cell migration-related genes often need to determine whether a candidate gene is causally involved in the process, and to dissect its mechanism of action. This requires precise genetic tools that can knock out, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such studies, from single-gene editing to genome-wide library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for lymphatic endothelial cell migration research.
Frequently Asked Questions About lymphatic endothelial cell migration
What is GO:1904977?
GO:1904977 is the Gene Ontology term for lymphatic endothelial cell migration, defined as the orderly movement of a lymphatic endothelial cell from one site to another in the wall of a lymphatic vessel.
What genes are involved in lymphatic endothelial cell migration?
Key genes include ANGPT2, ITGB1, RHOA, formins, EGFL7, ITGAV, ITGB3, MAFB, MAFBB, COL2A1, RGS5, and PAI-1.
How is lymphatic endothelial cell migration regulated?
It is regulated by growth factor signaling (e.g., ANGPT2-TIE2), integrin-mediated adhesion, RhoA-formin actin remodeling, and transcription factors such as MAFB and MAFBB.
Why is lymphatic endothelial cell migration important in cancer?
It drives tumor lymphangiogenesis and lymphatic metastasis, and is associated with acquired drug resistance in breast cancer.
What methods are used to study lymphatic endothelial cell migration?
Live imaging in zebrafish and mice, Transwell migration assays, CRISPR screens, RNA-seq, and proteomics are commonly used.
What is the role of ANGPT2 in lymphatic endothelial cell migration?
ANGPT2 stimulates migration through TIE2 and the β1 integrin-RhoA-formin axis.
How does EGFL7 affect lymphatic endothelial cell migration?
EGFL7 drives brain lymphatic endothelial cell development through integrin αvβ3.
What is the function of MAFB and MAFBB in lymphatic endothelial cell migration?
They differentially regulate migration in topographically distinct manners.
Can CRISPR be used to study lymphatic endothelial cell migration?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are widely used to dissect gene function in this process.
What diseases are associated with defective lymphatic endothelial cell migration?
Lymphedema, lymphatic dysplasia, cancer metastasis, and inflammatory lymphangiogenesis.
Conclusion
Lymphatic endothelial cell migration (GO:1904977) is a specialized biological process essential for lymphatic vascular development and function. It is controlled by a complex network of growth factors, adhesion molecules, cytoskeletal regulators, and transcription factors, with key roles for ANGPT2, ITGB1, RhoA, formins, EGFL7, MAFB, and MAFBB. Dysregulation of this process contributes to cancer metastasis, lymphedema, and inflammatory diseases, making it an important therapeutic target. Advances in CRISPR genome editing, live imaging, and omics technologies are accelerating the discovery of new regulators and mechanisms. EDITGENE provides comprehensive CRISPR services to support researchers in dissecting the genetic control of lymphatic endothelial cell migration.
References
- 1. Piao W et al.. 2025. Regulatory T cell and endothelial cell crosstalk.. Nat Rev Immunol 25(8):588-607 PMID: 40169744
- 2. Liu Q et al.. 2025. COL1A1-positive endothelial cells promote gastric cancer progression via the ANGPTL4-SDC4 axis driven by endothelial-to-mesenchymal transition.. Cancer Lett 623:217731 PMID: 40254092
- 3. Qiu C et al.. 2024. RGS5(+) lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism.. Drug Resist Updat 77:101149 PMID: 39306871
- 4. Wei WF et al.. 2023. Cancer-associated fibroblast-derived PAI-1 promotes lymphatic metastasis via the induction of EndoMT in lymphatic endothelial cells.. J Exp Clin Cancer Res 42(1):160 PMID: 37415190
- 5. Chaudhury S et al.. 2020. Localised Collagen2a1 secretion supports lymphatic endothelial cell migration in the zebrafish embryo.. Development 147(18) PMID: 32839180
- 6. Chen J et al.. 2024. Epidermal growth factor-like domain 7 drives brain lymphatic endothelial cell development through integrin αvβ3.. Nat Commun 15(1):5986 PMID: 39013903
- 7. Akwii RG et al.. 2022. Angiopoietin-2-induced lymphatic endothelial cell migration drives lymphangiogenesis via the β1 integrin-RhoA-formin axis.. Angiogenesis 25(3):373-396 PMID: 35103877
- 8. Arnold H et al.. 2022. mafba and mafbb differentially regulate lymphatic endothelial cell migration in topographically distinct manners.. Cell Rep 39(12):110982 PMID: 35732122
